Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a pro‑drug that, after intramuscular injection, is gradually hydrolyzed to active testosterone. The hormone then binds to androgen receptors in target cells, influencing gene expression that drives anabolic activities, supports erythropoiesis, and maintains secondary sexual characteristics.

The dosing regimen for Nebido is determined by the prescribing physician based on the patient’s clinical condition, serum testosterone levels, and response to therapy. Typically, the medication is administered as an intramuscular injection at intervals recommended by the clinician.

Nebido is not indicated for use in pregnant or breastfeeding individuals. Safety data are lacking, and testosterone therapy can affect fetal development and milk production. It should be avoided in these populations unless a clear medical necessity is established by a qualified health professional.

To request Nebido, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Nebido offers a long‑acting formulation that can be given every 10‑14 weeks, reducing injection frequency compared with short‑acting testosterone esters that require weekly or bi‑weekly dosing. This convenience can improve adherence, though individual response and side‑effect profiles should be evaluated when selecting a therapy.

Nebido must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the product. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

Nebido is administered by a qualified health‑care professional as an intramuscular injection, usually into the gluteal muscle. The injection should be performed using aseptic technique, and the dosing interval is set by the prescriber based on therapeutic response.

Serious adverse events include polycythemia (elevated red blood cell count), cardiovascular complications such as myocardial infarction or stroke, worsening of sleep‑apnea, and potential progression of prostate disease. Patients should be monitored regularly for hematocrit, cardiovascular status, and prostate health.

Nebido is contraindicated in individuals with known hypersensitivity to testosterone undecanoate, active prostate cancer, severe untreated sleep‑apnea, uncontrolled heart failure, or those who are pregnant or breastfeeding. Caution is also advised for patients with significant liver disease or a history of thromboembolic events.